ICER outlines alternatives to pharma rebates

13 March 2019

Reflecting its growing standing as an opinion leader on all things drug price-related, the USA's Institute for Clinical and Economic Review (ICER) - in collaboration with the Office of Health Economics (OHE) - has published a white paper looking at alternative models for pharmaceutical rebates in the USA.

The paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future innovation.

The ICER claims that it could be a guide for policymakers as they consider multiple options, including those recently proposed by the Trump Administration.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK